Epigenetic approaches to overcoming chemotherapy resistance
Mené sur 25 patients atteints d'une tumeur solide de stade avancé, cet essai de phase I évalue la toxicité et l'activité antitumorale d'un composé appelé RRx-001 dont le mécanisme d'action est de nature épigénétique
Tumour cells are well known to develop genetic alterations that cause drug resistance during disease progression. These acquired genetic changes and resistance patterns were long thought to be permanent and unalterable, which led to the assumption that a tumour that has progressed after treatment needs a different non-cross-resistant treatment plan. However, growing data of epigenetic changes to the transcriptional potential of cancer cells during tumour progression are transforming this picture.
The Lancet Oncology , commentaire, 2014